Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 47, 2017 - Issue 12
Submit an article Journal homepage
603
Views
8
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib

Nobuo SekiguchiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, JapanCorrespondence[email protected]
,
Shunsuke NagaoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
,
Kenji TakanashiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
,
Motohiro KatoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
,
Akihisa KanekoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
,
Keiichi MoritaResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
,
Hidetoshi ShindohResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
&
Masaki IshigaiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
 show all
Pages 1042-1051 | Received 30 Sep 2016, Accepted 12 Nov 2016, Published online: 01 Dec 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Gobardhan Bal, Lakshmi Kanakaraj & Bibhash Chandra Mohanta. (2023) Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studies. Xenobiotica 53:12, pages 621-633.
Read now
Yourong Zhou, Yiming Yin, Jiangxin Xu, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan & Xiaochun Yang. (2023) An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert Opinion on Pharmacotherapy 24:12, pages 1361-1373.
Read now

Articles from other publishers (6)

Ya-nan Liu, Jie Chen, Jing Wang, Qingqing Li, Guo-xin Hu, Jian-ping Cai, Guanyang Lin & Ren-ai Xu. (2023) Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism. Archives of Toxicology 97:8, pages 2133-2142.
Crossref
Ondrej Bilek, Milos Holanek, Jan Jurica, Sona Stepankova, Jiri Vasina, Iveta Selingerova, Alexandr Poprach, Simona Borilova, Tomas Kazda, Igor Kiss & Lenka Zdrazilova-Dubska. (2021) Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. International Immunopharmacology 99, pages 108012.
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Takeshi Hirota, Shota Muraki & Ichiro Ieiri. (2018) Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clinical Pharmacokinetics 58:4, pages 403-420.
Crossref
Yumi Cleary, Michael Gertz, Peter N. Morcos, Li Yu, Kuresh Youdim, Alex Phipps, Stephen Fowler & Neil Parrott. (2017) Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development. Clinical Pharmacology & Therapeutics 104:3, pages 505-514.
Crossref
Stephen Fowler, Peter N. Morcos, Yumi Cleary, Meret Martin-Facklam, Neil Parrott, Michael Gertz & Li Yu. (2017) Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. Current Pharmacology Reports 3:1, pages 36-49.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.